<unk>  crosses the blood-brain-barrier and acts as a TAAR1 agonist, functioning as a selective norepinephrine releasing agent (with few or no effects on the release of dopamine), so it affects the central nervous system, although its effects are qualitatively distinct relative to those of dextromethamphetamine. It does not possess the potential for euphoria or addiction that dextromethamphetamine possesses. Among its physiological effects are the vasoconstriction that makes it useful for nasal decongestion. The elimination half-life of<unk>  is between 13.3 and 15 hours, whereas dextromethamphetamine has a half-life of about 10.5 hours. Selegiline<unk>  is an active metabolite of the antiparkinson's drug selegiline. Selegiline, a selective monoamine oxidase B (MAOB) inhibitor at low doses, is also metabolized into<unk>  and levoamphetamine. This has caused users to test positive for amphetamines. Selegiline itself has neuroprotective and neuro-rescuing effects, but concern over the resulting<unk> 's neurotoxicity led to development of alternative MAOB inhibitors, such as rasagiline, that do not produce toxic metabolites.
Levomethamphetamine
Propylamphetamine
Dextroamphetamine
Levoamphetamine
Butriptyline
Triazolam
Perphenazine
Methoxyphenamine